Cat Allergy Vaccine: SCIT, HypoCat, and LiveClear Explained for Humans
'Cat allergy vaccine' is a colloquial search term meaning three different things: (1) human SCIT or SLIT immunotherapy with FDA-standardized cat extract; (2) HypoCat — an experimental virus-like-particle vaccine given to the CAT to reduce its Fel d 1 production — veterinary research; (3) Purina LiveClear — anti-Fel d 1 IgY in cat food — a veterinary nutrition product. This page covers option 1.
8 peer-reviewed sources
'Cat allergy vaccine' colloquially means SCIT or SLIT for humans sensitized to Fel d 1. FDA-standardized cat extract (Greer license #308) and DBPC RCTs support ~72% symptom reduction. No one-shot vaccine equivalent exists for human cat allergy as of 2026.
The essentials
'Cat allergy vaccine' is a colloquial search term that means three different things. (1) HUMAN SCIT or SLIT immunotherapy with FDA-standardized cat extract. (2) HypoCat — an experimental virus-like-particle vaccine given to the CAT to reduce its own Fel d 1 production — veterinary research, not for humans. (3) Purina LiveClear — anti-Fel d 1 IgY antibodies in cat food — a veterinary nutrition product, not a human allergy treatment. This page covers option (1) — human SCIT and SLIT immunotherapy.
The first misunderstanding baked into 'cat allergy vaccine' is the word 'vaccine' itself. In the public-health sense, a vaccine is a one-time inoculation that confers durable immunity to an infection — like influenza or polio vaccines. Allergy immunotherapy is the opposite mechanism: repeated controlled exposure to a protein YOU are already allergic to, in escalating doses, to induce immune tolerance. It is not conferred immunity; it is trained tolerance. The WHO/IUIS and AAAAI/ACAAI consistently use 'allergen immunotherapy' (AIT), 'subcutaneous immunotherapy' (SCIT), or 'sublingual immunotherapy' (SLIT) — never 'vaccine' in the clinical literature.
The HUMAN cat-allergy treatment on the US market is SCIT using FDA-standardized cat-hair or cat-pelt extract at 10,000 BAU/mL (Greer license #308, FDA CBER) — the only FDA-standardized mammalian allergen extracts in the US. That same SCIT is now available as an at-home allergy shot kit from Curex for patients who want to avoid weekly clinic visits, with off-label SLIT drops standing as a separate needle-free modality. Calling any of these a 'vaccine' is colloquial. Curex provides at-home IgE component testing with allergist review for Fel d 1 — the 35–38 kDa secretoglobin that sensitizes 90 to 96 percent of cat-allergic patients per Satyaraj 2019 — to confirm that the symptoms attributed to cat exposure are actually driven by cat-specific IgE rather than cross-reactive lipocalin sensitization from another mammal.
The second misunderstanding is HypoCat (Thoms F et al., Viruses 2020), an experimental vaccine that immunizes the CAT itself against its own Fel d 1 protein using a virus-like-particle platform. In Phase 1/2 trials, injecting the cat reduced the cat's serum Fel d 1 levels and allergen exposure for nearby humans. This is veterinary research and has not been approved for sale as of 2026 — it is not a human treatment. Nestlé Purina LiveClear (Satyaraj E et al., Immun Inflamm Dis 2019;7[2]:68–73) uses anti-Fel d 1 IgY chicken antibodies fed to the cat in food; it reduces active Fel d 1 in cat saliva by approximately 47% on average. Also a veterinary nutrition product, not a human allergy treatment.
A third experimental category: Regeneron's REGN1908-1909 anti-Fel d 1 monoclonal antibody program (Orengo JM et al., Nat Commun 2018) showed ~85% symptom reduction at nasal challenge in a single trial. This is for humans but remains experimental and is not approved for routine use as of 2026.
How allergy shots retrain your immune system
Human cat immunotherapy (SCIT or SLIT) works by repeatedly exposing the immune system to Fel d 1 in escalating doses, shifting the allergic IgE response toward IgG4 blocking antibodies and T-regulatory cell tolerance. This mechanism is fundamentally different from a vaccine: no pathogen is targeted, no one-time inoculation is given, and the process requires years of consistent exposure rather than a single dose.
Component-Resolved Confirmation
Testing for Fel d 1 specifically (not total cat extract IgE) confirms whether the patient is actually sensitized to the cat-specific secretoglobin. Fel d 4 cross-reactivity with horse (Equ c 1, 67% identity) or dog (Can f 6) can mimic cat sensitization and would require different immunotherapy targeting.
Build-Up Phase (~26 weeks)
Weekly escalating injections (or daily increasing SLIT drops) from a fraction of the therapeutic dose to the maintenance level. A 30-minute post-injection observation period is mandatory for every SCIT visit.
Maintenance Phase (3–5 years)
Sustained allergen exposure at the therapeutic dose induces long-term immune remodeling: IL-10 and TGF-beta secretion by T-regulatory cells, reduction in Th2 cytokines, decrease in tissue eosinophils and mast cells. These changes persist after treatment ends — unlike the pharmacological effect of antihistamines, which reverses immediately.
Post-Treatment Remission
Durham SR et al. (NEJM 1999;341:468–475) demonstrated at least 4-year sustained remission after a 3-year SCIT course. Post-treatment benefit is estimated at 7–12 years after a complete course. This durability is the closest human cat immunotherapy gets to the 'vaccine-like' outcome patients are seeking.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
The human cat immunotherapy timeline — whether SCIT or SLIT — requires 3–5 years for durable disease modification. This contrasts with the single-dose or short-course model implied by 'vaccine.' There is no accelerated protocol for cat immunotherapy that achieves equivalent outcomes in fewer visits.
For SCIT: approximately 26 weekly in-office injections with mandatory 30-minute post-injection observation. For SLIT drops: daily at-home dose escalation with initial supervised first dose.
SCIT maintenance: approximately 14–20 clinic visits/year. SLIT drops: daily home administration. The minimum 3-year duration is required for durable disease modification per Cox 2011 PP3.
After completing the course, immune tolerance persists. This durable remission is the aspect most analogous to what patients mean by 'vaccine-like' effect — but it requires the full 3-to-5-year treatment investment to achieve.
Efficacy by allergen — what the data shows
Human cat immunotherapy (SCIT and SLIT) has the strongest evidence base of any pet-allergen treatment. The FDA-standardized extract enables consistent dosing. HypoCat (veterinary) and REGN1908-1909 (experimental human) represent future directions that may improve upon current options but are not available for routine use.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Cat-allergic patients in 2026 have two evidence-based human immunotherapy modalities — SCIT (now available either in-office or as an at-home allergy shot kit) and needle-free SLIT drops — plus experimental non-immunotherapy approaches. HypoCat and LiveClear reduce allergen in the cat's environment rather than treating the human's immune response.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
Human At-Home SCIT (Curex) | |||||
Human SLIT Drops (needle-free) | |||||
HypoCat (veterinary experimental — NOT a human treatment) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex delivers the at-home cat allergy shot kit (SCIT) for $129/month all-inclusive — the FDA-standardized Fel d 1 immunotherapy behind the ~72% DBPC data, given as one weekly shot at home instead of weekly clinic visits. The personalized serum is sterile-compounded to USP <797>, a board-certified allergist oversees the plan, your first dose and every dose change are supervised live over Zoom, and a prescribed epinephrine auto-injector is confirmed on hand.
See if at-home shots are right for youSide effects — what to watch for
Human SCIT and SLIT drops have distinct safety profiles. SCIT carries a small systemic reaction risk requiring at-home observation; SLIT drops have no confirmed fatalities and primarily cause oral-local reactions.
Insurance coverage — what to expect
Human cat SCIT is covered by major commercial insurers and Medicare Part B when standard medical necessity criteria are met. For full insurer details, see /allergy-shots/cost/does-insurance-cover-allergy-shots.
Skip the insurance hassle — Curex is $129/mo flat, no insurance needed.
Start free assessmentFrequently asked questions
Is there a one-shot vaccine that cures cat allergy?
No. As of 2026, no one-shot vaccine for human cat allergy exists or is approved. The closest approved human option is subcutaneous immunotherapy (SCIT) over 3–5 years, which produces approximately 72% symptom reduction in DBPC RCTs (Varney 1997 Clin Exp Allergy) and approximately 7–12 years of post-treatment remission after a complete course (Durham 1999 NEJM framework extrapolated to cat). The experimental REGN1908-1909 anti-Fel d 1 monoclonal antibody (Orengo 2018 Nat Commun) showed ~85% symptom reduction in a single trial but is not approved for routine use. The concept of a one-dose vaccine for an IgE-mediated allergy — which requires years of immune retraining — remains a research goal rather than a clinical reality.
What is the HypoCat vaccine and is it for humans?
HypoCat is an experimental virus-like-particle (VLP) vaccine developed by researchers at the University of Zurich (Thoms F et al., Viruses 2020) that immunizes the CAT against its own Fel d 1 protein. When injected into cats, it stimulates the cat to produce antibodies against Fel d 1, reducing the cat's Fel d 1 output. Early trials showed reduced Fel d 1 levels in cat serum and potentially reduced allergen shedding. HypoCat is NOT a human allergy treatment — it does not modify the human's immune response. It is a veterinary research product, not approved for sale as of 2026. For humans, the approved treatment options remain SCIT and SLIT.
Does Purina LiveClear reduce cat allergy in humans?
Purina LiveClear is a cat food containing chicken egg-derived anti-Fel d 1 IgY antibodies that bind Fel d 1 in the cat's saliva, reducing active Fel d 1 deposition. Satyaraj E et al. (Immun Inflamm Dis 2019;7[2]:68–73) reported approximately 47% reduction in active Fel d 1 in cat saliva after 3 weeks on the diet. It is a veterinary nutrition product — it reduces allergen at the source (the cat) rather than modifying the human's immune system. It does not prevent IgE-mediated allergic reactions and is not a substitute for human immunotherapy. Some cat-allergic individuals may experience reduced symptoms if their cat's Fel d 1 output decreases, but LiveClear does not treat or modify the human allergy itself.
Why do allergists not call allergy shots a vaccine?
Clinically, 'vaccine' in the public-health sense refers to a product that confers protective immunity against an external pathogen — a virus, bacterium, or toxin — typically in one or a few doses. Allergy immunotherapy (AIT) is fundamentally different: it modulates an overactive IgE response to an environmental protein the patient is already exposed to, requiring years of repeated exposure to retrain immune tolerance. The WHO/IUIS and AAAAI/ACAAI terminology guidance (Bousquet J et al., JACI 1998;102[4 Pt 1]:558–562) uses 'allergen immunotherapy,' 'SCIT,' or 'SLIT' — not 'vaccine.' While some researchers use 'allergy vaccine' informally to describe peptide or mRNA-based AIT research platforms (like HypoCat), the clinical standard is to reserve 'vaccine' for prophylactic infectious-disease products.
Are there any approved cat allergy treatments that don't require years of shots?
Anti-IgE therapy with omalizumab (Xolair) is not approved for cat allergy specifically, though it has been studied in cat-allergic asthmatics (Massanari M et al., Allergy Asthma Proc 2009: ~50% reduction in exacerbations). Xolair was FDA-approved in February 2024 for prevention of reactions from accidental food-allergen exposure — a different indication from cat allergy. Daily pharmacotherapy (antihistamines, nasal corticosteroids) provides symptomatic control without disease modification and must continue indefinitely. As of 2026, the only disease-modifying options for human cat allergy requiring less than 3-year commitment are experimental. SCIT (3–5 years) and at-home SLIT drops (3–5 years of daily use) remain the established pathways.
Can any cat breed be called truly hypoallergenic?
No domestic cat breed is truly hypoallergenic. All cats produce Fel d 1, which sensitizes 90–96% of cat-allergic patients and accounts for 60–90% of total cat-allergen IgE reactivity (Grönlund H et al., Int Arch Allergy Immunol 2010). Hilger C et al. (PMC10975736, 2024) confirmed that hairless Sphynx cats — the most commonly marketed hypoallergenic breed — still produce Fel d 1. NHANES 2005–2006 (Salo PM et al., JACI 2014) detected Fel d 1 in 99.9% of US homes including cat-free homes. Intact male cats produce 3–5 times more Fel d 1 than neutered males (Kelly SM et al., JACI 2018), so neutering reduces but does not eliminate allergen load. No 'hypoallergenic' breed claim has been validated by allergen measurement data.
Related Articles
Allergy Shots for Dog Allergy | Curex Component-First Guide
Allergy shots for dog allergy treat HUMANS. Before you start, test Can f 1 vs Can f 5 — 16.5% can skip shots entirely. Dog SCIT evidence is 'poor and conflicting' (Smith 2016).
Read moreCat Allergy Shot for Humans | Curex SCIT Guide
This page covers cat allergy shots FOR HUMANS — SCIT with FDA-standardized Fel d 1 extract (10,000 BAU/mL). Not Cytopoint. Not Apoquel. ~72% symptom reduction in RCTs.
Read moreAllergy Shots for Cat Allergy | Full SCIT Guide | Curex
Allergy shots for cat allergies reduce symptoms 60-72% at the 15 mcg Fel d 1 maintenance dose. Cat SCIT efficacy, dosing, and alternatives.
Read moreAllergy Shots for Kids: PAT Study & Age Guide | Curex
Allergy shots from age 5. PAT study: 3 yrs SCIT halves asthma risk (OR 4.6). At-home SCIT via Curex for eligible pediatric families.
Read moreAllergy Shots for Dog Allergies | Curex Human SCIT Guide
Allergy shots for dog allergies treat HUMANS — not dogs. Dog SCIT evidence is 'poor and conflicting' (Smith 2016). 16.5% of dog-sensitized adults can skip shots entirely.
Read moreAre Allergy Shots Effective? | Curex Guide
Are allergy shots effective? Cochrane meta-analysis of 51 RCTs (n=2,871) found symptom SMD −0.73. Per-allergen rates: venom 95%+, grass 80%, cat 62%. Full evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.